Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

EndoTex to start pivotal carotid stent trial:

This article was originally published in Clinica

Executive Summary

The US FDA has given EndoTex Interventional Systems the go-ahead to begin a pivotal study of its NexStent self-expanding carotid stent. The study, called CABERNET, will enrol patients at high-risk for surgical carotid endarterectomy across 30 US and European sites. Following a series of deals between Endotex and Boston Scientific last year, the trial will test the stent together with Boston's filterwire embolic protection device. The agreements also provided for Boston to make an equity investment in Endotex and to gain an exclusive option to buy the firm. Boston will be the primary distributor for Cupertino, California-based Endotex in international markets.

Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

MT064560

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel